{"product_id":"medical-device-manufacturing-business-planning","title":"How to Write a Business Plan in 7 Steps: Medical Device Manufacturing","description":"\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"line_top\"\u003e\u003c\/div\u003e\n\u003ch2\u003eHow to Write a Business Plan for Medical Device Manufacturing\u003c\/h2\u003e\n\u003cp\u003eThis guide helps founders structure their plan, focusing on critical areas like FDA compliance, high fixed costs (starting at $43,800 monthly), and scaling EBITDA from $312 million (Year 1) to $2537 million (Year 5)\n\n\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\" id=\"main_article_image\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003e\u003cspan style=\"color: #6067F2;\"\u003eHow to Write a Business Plan for Medical Device Manufacturing in 7 Steps\u003c\/span\u003e\u003c\/h2\u003e\u003cbr\u003e\n\u003ctable id=\"dwnld_tbl_id\"\u003e\n\u003ctr\u003e\n\u003cth\u003e#\u003c\/th\u003e\n\u003cth\u003eStep Name\u003c\/th\u003e\n\u003cth\u003ePlan Section\u003c\/th\u003e\n\u003cth\u003eKey Focus\u003c\/th\u003e\n\u003cth\u003eMain Output\/Deliverable\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eDefine Product \u0026amp; Regulatory Strategy\u003c\/td\u003e\n\u003ctd\u003eConcept\u003c\/td\u003e\n\u003ctd\u003eDetail five devices, FDA classification, and QMS needs\u003c\/td\u003e\n\u003ctd\u003eRegulatory pathway defined\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eTarget Market \u0026amp; Sales Model\u003c\/td\u003e\n\u003ctd\u003eMarket\u003c\/td\u003e\n\u003ctd\u003eIdentify hospital systems; project sales growth (100 units 2026 to 550 units 2030)\u003c\/td\u003e\n\u003ctd\u003eSales forecast structure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003eEstablish Manufacturing \u0026amp; COGS\u003c\/td\u003e\n\u003ctd\u003eOperations\u003c\/td\u003e\n\u003ctd\u003eOutline production; $200,000 Cleanroom CapEx; calculate unit costs\u003c\/td\u003e\n\u003ctd\u003eDetailed unit cost model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003eModel Capital Expenditures\u003c\/td\u003e\n\u003ctd\u003eFinancials\u003c\/td\u003e\n\u003ctd\u003eItemize $1,115,000 CapEx; confirm $43,800 monthly OpEx\u003c\/td\u003e\n\u003ctd\u003eCapEx schedule and fixed costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003ctd\u003eBuild the Organizational Chart\u003c\/td\u003e\n\u003ctd\u003eTeam\u003c\/td\u003e\n\u003ctd\u003eDetail initial 65 FTEs; justify R\u0026amp;D salary ($180,000)\u003c\/td\u003e\n\u003ctd\u003eInitial staffing plan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003ctd\u003eCreate 5-Year Financial Projections\u003c\/td\u003e\n\u003ctd\u003eFinancials\u003c\/td\u003e\n\u003ctd\u003eForecast revenue; confirm aggressive breakeven target of Month 1\u003c\/td\u003e\n\u003ctd\u003e5-year P\u0026amp;L forecast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003ctd\u003eDetermine Funding Needs \u0026amp; Risks\u003c\/td\u003e\n\u003ctd\u003eRisks\u003c\/td\u003e\n\u003ctd\u003eCalculate $1,097,000 minimum cash need; analyze 7116% ROE\u003c\/td\u003e\n\u003ctd\u003eFunding requirement summary\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cdiv class=\"dwnld_btn_div\"\u003e\u003cbutton id=\"dwnld_btn_id\" class=\"dwnld_btn_clss\"\u003eDownload Table in XLSX\u003c\/button\u003e\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e \u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eWhat specific regulatory pathway must our devices follow for FDA approval?\n\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eThe regulatory pathway for the Medical Device Manufacturing business hinges entirely on classifying their surgical tools and diagnostic equipment as Class I, II, or III devices, which dictates the required FDA submission—likely a \u003cstrong\u003e510(k)\u003c\/strong\u003e for many surgical tools—and subsequent timeline risks; understanding this upfront is crucial for accurate capital planning, as detailed in \u003ca href=\"\/blogs\/kpi-metrics\/medical-device-manufacturing\"\u003eWhat Is The Primary Metric That Reflects The Success Of Your Medical Device Manufacturing Business?\u003c\/a\u003e\u003c\/p\u003e\n\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eDevice Classification Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eClass I devices often require only registration and listing; these are low-risk tools.\u003c\/li\u003e\n\u003cli\u003eClass II devices typically need a 510(k) premarket notification, taking roughly \u003cstrong\u003e90 days\u003c\/strong\u003e review time post-submission.\u003c\/li\u003e\n\u003cli\u003eClass III devices, high-risk novel tech, require a PMA (Premarket Approval), which can take \u003cstrong\u003e1–3 years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIf your diagnostic equipment is novel, defintely budget for the longer PMA timeline to avoid cash flow surprises.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eOngoing Compliance Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003ePost-market surveillance requires mandatory Medical Device Reporting (MDR) for adverse events.\u003c\/li\u003e\n\u003cli\u003eAnnual FDA establishment registration costs \u003cstrong\u003e$5,400\u003c\/strong\u003e for the current cycle.\u003c\/li\u003e\n\u003cli\u003eQuality System Regulation (QSR) compliance demands ongoing audits and documentation upkeep.\u003c\/li\u003e\n\u003cli\u003eExpect \u003cstrong\u003e10% to 15%\u003c\/strong\u003e of initial R\u0026amp;D costs to recur annually for compliance maintenance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eHow will we fund the $1115 million in initial capital expenditures (CapEx)?\n\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eFunding the \u003cstrong\u003e$1.115 billion\u003c\/strong\u003e initial Capital Expenditures (CapEx) for Medical Device Manufacturing requires balancing debt capacity against equity dilution while maintaining a \u003cstrong\u003e$1.097 billion\u003c\/strong\u003e cash reserve; this structure must support the modeled \u003cstrong\u003e0.49% Internal Rate of Return (IRR)\u003c\/strong\u003e, a return profile that demands careful comparison against industry benchmarks, which you can read more about here: \u003ca href=\"\/blogs\/how-much-makes\/medical-device-manufacturing\"\u003eHow Much Does The Owner Of Medical Device Manufacturing Business Typically Make?\u003c\/a\u003e. We need to secure roughly \u003cstrong\u003e$2.212 billion\u003c\/strong\u003e total before breaking ground.\u003c\/p\u003e\n\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eFunding Mix Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eDetermine the optimal debt-to-equity ratio for the \u003cstrong\u003e$2.212 billion\u003c\/strong\u003e requirement.\u003c\/li\u003e\n\u003cli\u003eUse equity for initial site acquisition and tooling costs.\u003c\/li\u003e\n\u003cli\u003eSecure long-term debt based on projected asset collateral value.\u003c\/li\u003e\n\u003cli\u003eAnalyze covenants tied to debt servicing capacity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eBuffer and Return Targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eThe \u003cstrong\u003e$1.097 billion\u003c\/strong\u003e cash buffer must cover initial operating losses.\u003c\/li\u003e\n\u003cli\u003eModel the cash burn rate to ensure the buffer lasts until positive cash flow is achieved, defintely.\u003c\/li\u003e\n\u003cli\u003eA \u003cstrong\u003e0.49% IRR\u003c\/strong\u003e suggests heavy reliance on terminal value or very long payback periods.\u003c\/li\u003e\n\u003cli\u003eStress test revenue ramp assumptions supporting the \u003cstrong\u003e0.49%\u003c\/strong\u003e hurdle rate.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eWhat is the true fully-loaded Cost of Goods Sold (COGS) for each device?\n\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eThe true fully-loaded Cost of Goods Sold (COGS) for each device requires separating direct variable unit costs from revenue-based overhead to establish defensible gross margin targets.\u003c\/p\u003e\n\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003ePinpoint Variable Unit Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eIsolate direct material costs, like the \u003cstrong\u003e$50 material cost\u003c\/strong\u003e for a surgical stapler component.\u003c\/li\u003e\n\u003cli\u003eAdd direct labor and any unit-specific overhead tied to the production line.\u003c\/li\u003e\n\u003cli\u003eThis sum forms your baseline cost floor before allocating any fees tied to sales volume.\u003c\/li\u003e\n\u003cli\u003eIf you don't track this precisely, margin erosion is defintely possible.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eSet Gross Margin Targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eLayer revenue-based overhead, such as the \u003cstrong\u003e15% regulatory and QA fees\u003c\/strong\u003e, on top of variable COGS.\u003c\/li\u003e\n\u003cli\u003eThese fees scale with revenue, unlike fixed factory rent, so they must be baked into the selling price.\u003c\/li\u003e\n\u003cli\u003eUnderstanding this structure helps determine if the Medical Device Manufacturing business is achieving sustainable profitability; \u003ca href=\"\/blogs\/profitability\/medical-device-manufacturing\"\u003eIs The Medical Device Manufacturing Business Achieving Sustainable Profitability?\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eYour target gross margin must absorb these costs and still cover operating expenses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eDo we have the specialized talent needed for R\u0026amp;D and Quality Control (QC)?\n\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003e$897,500\u003c\/strong\u003e Year 1 salary budget is justified by immediately securing the Regulatory Affairs Manager, which is essential groundwork before scaling engineering staff from \u003cstrong\u003e10 FTE\u003c\/strong\u003e to \u003cstrong\u003e30 FTE\u003c\/strong\u003e by 2030. This upfront investment in compliance de-risks future product launches for the Medical Device Manufacturing operation.\u003c\/p\u003e\n\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eSecuring Year 1 Compliance Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eThe Regulatory Affairs Manager salary of \u003cstrong\u003e$130,000\u003c\/strong\u003e is a critical part of the \u003cstrong\u003e$897,500\u003c\/strong\u003e total Year 1 compensation outlay.\u003c\/li\u003e\n\u003cli\u003eThis role is needed now to manage FDA submissions for the focused portfolio of devices.\u003c\/li\u003e\n\u003cli\u003eWe defintely need this expertise before adding significant R\u0026amp;D headcount.\u003c\/li\u003e\n\u003cli\u003eIf onboarding takes 14+ days, churn risk rises among early hires.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eEngineering Scale and Quality Control Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eThe plan requires scaling engineering from \u003cstrong\u003e10 FTE\u003c\/strong\u003e today up to \u003cstrong\u003e30 FTE\u003c\/strong\u003e by 2030.\u003c\/li\u003e\n\u003cli\u003eEach new engineer demands robust Quality Control (QC) oversight during product design.\u003c\/li\u003e\n\u003cli\u003eThis initial staffing supports the multi-year product launch schedule.\u003c\/li\u003e\n\u003cli\u003eUnderstanding this long-term talent pipeline helps assess if the Medical Device Manufacturing business is achieving sustainable profitability; see \u003ca href=\"\/blogs\/profitability\/medical-device-manufacturing\"\u003eIs The Medical Device Manufacturing Business Achieving Sustainable Profitability?\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e \u003cdiv class=\"card_smpl\"\u003e\n\n\u003cdiv class=\"double_border\"\u003e\n\n\u003cdiv class=\"card_smpl_header\"\u003e\n\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-plus-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\n\n\u003ch3\u003eKey Takeaways\u003c\/h3\u003e\n\n\u003c\/div\u003e\n\n\u003cul class=\"lst_crct_blog\"\u003e\n\n\u003cli\u003eSuccessfully justifying the $1,115 million initial Capital Expenditure (CapEx) and securing a minimum cash buffer of $1,097 million are mandatory prerequisites for funding the startup phase.\u003c\/li\u003e\n\n\u003cli\u003eThe financial model must demonstrate aggressive scalability by projecting EBITDA growth from $312 million in Year 1 to $2,537 million by Year 5, justifying an ambitious 7,116% Return on Equity (ROE).\u003c\/li\u003e\n\n\u003cli\u003eRegulatory strategy dictates operational structure, demanding immediate investment in specialized talent, such as a $130,000 Regulatory Affairs Manager, and defining the specific FDA pathway for all five core devices.\u003c\/li\u003e\n\n\u003cli\u003eAccurate Cost of Goods Sold (COGS) modeling requires separating variable unit costs, like $50 for materials, from revenue-based overhead fees to ensure high gross margin targets are met.\u003c\/li\u003e\n\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eStep 1\n: \u003cspan style=\"color: #126CFF;\"\u003eDefine Product \u0026amp; Regulatory Strategy\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n\u003cdiv class=\"left-row1\"\u003e\n\u003ch3\u003eRegulatory Path Lock\u003c\/h3\u003e\n\u003cp\u003eDefining these five devices locks in your regulatory path and dictates the compliance timeline. Each product needs a defined intended use to determine its FDA classification—Class I, II, or III. This classification directly drives your Quality Management System (QMS) compliance burden. Getting this wrong delays market entry, jeopardizing the aggressive \u003cstrong\u003eMonth 1 breakeven\u003c\/strong\u003e target.\u003c\/p\u003e\n\u003cp\u003eThe QMS, often based on \u003cstrong\u003e21 CFR Part 820\u003c\/strong\u003e, must be ready before the \u003cstrong\u003eCleanroom Setup ($200,000 CapEx\u003c\/strong\u003e) is fully validated for production. If onboarding regulatory expertise takes too long, the $180,000 Head of R\u0026amp;D salary becomes pure burn before revenue starts flowing from your planned unit sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"right-row1\"\u003e\n\u003cdiv class=\"tips-box\"\u003e\n\u003ch3\u003eActionable Classification\u003c\/h3\u003e\n\u003cp\u003eMap the five devices immediately to their likely FDA class based on risk. Surgical tools are often Class II, requiring 510(k) clearance, while simple diagnostic aids might be Class I. This classification determines whether you need a full QMS audit or just basic design controls documentation right now.\u003c\/p\u003e\n\u003cp\u003eImplement a lean QMS from day one, focusing documentation efforts on the highest-risk items—likely the diagnostic equipment. Documenting processes now saves expensive rework later, which is critical when managing \u003cstrong\u003e$43,800 monthly fixed OpEx\u003c\/strong\u003e. Don't wait for the first unit sale to finalize your control procedures; they are part of the product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"step-circle step1\"\u003e1\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003eStep 2\n: \u003cspan style=\"color: #126CFF;\"\u003eTarget Market \u0026amp; Sales Model\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n\u003cdiv class=\"right-row2\"\u003e\n\u003ch3\u003eCustomer Channel Lock\u003c\/h3\u003e\n\u003cp\u003eYou need to know exactly who writes the check—\u003cstrong\u003ehospital systems\u003c\/strong\u003e and large \u003cstrong\u003edistributors\u003c\/strong\u003e are your primary customers, not individual clinics. This choice dictates your sales cycle length and required regulatory support. If you plan to ship just \u003cstrong\u003e100 Portable Ultrasounds\u003c\/strong\u003e in 2026, that initial volume is highly dependent on signing just a few major accounts. This channel choice is defintely the make-or-break factor for early revenue stability.\u003c\/p\u003e\n\u003cp\u003eThe immediate financial pressure comes from the sales terms. You must model aggressively against the stated \u003cstrong\u003e50% commission\u003c\/strong\u003e structure for 2026. This high take rate means your unit economics must support a massive upfront cost just to get the device placed. You’re betting that volume growth, hitting \u003cstrong\u003e550 units\u003c\/strong\u003e by 2030, will eventually dilute the impact of that initial high commission rate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"left-row2\"\u003e\n\u003cdiv class=\"tips-box\"\u003e\n\u003ch3\u003eSales Growth Levers\u003c\/h3\u003e\n\u003cp\u003eYour action item is locking down those anchor contracts now. Selling direct requires significant internal sales headcount, but it gives you control over pricing and data. If you rely on distributors, ensure your contract defines clear volume tiers that automatically reduce the \u003cstrong\u003e50% commission\u003c\/strong\u003e percentage as you cross certain shipment thresholds.\u003c\/p\u003e\n\u003cp\u003eTo support the projection of moving from 100 units in 2026 to 550 units in 2030, you must have a clear plan for expanding your sales territory or product line coverage. What drives the next 450 units? If the price per unit is $1,000, that first year’s commission eats up $500 per unit before you even look at manufacturing costs. That margin pressure is real.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"step-circle step2\"\u003e2\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003eStep 3\n: \u003cspan style=\"color: #126CFF;\"\u003eEstablish Manufacturing \u0026amp; COGS\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n\u003cdiv class=\"left-row3\"\u003e\n\u003ch3\u003eManufacturing Foundation\u003c\/h3\u003e\n\u003cp\u003eEstablishing production sets your gross margin, which is the bedrock of valuation. The initial \u003cstrong\u003e$200,000\u003c\/strong\u003e Cleanroom Setup capital expenditure (CapEx) is non-negotiable for quality compliance in medical devices. Defintely get this right, because errors here cascade into regulatory risk and higher rework costs later.\u003c\/p\u003e\n\u003cp\u003eThis step ties directly to your US-based manufacturing promise. You need clear line-of-sight on assembly time and material overhead for all five devices before setting final pricing. Don't underestimate the overhead required just to maintain the controlled environment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"right-row3\"\u003e\n\u003cdiv class=\"tips-box\"\u003e\n\u003ch3\u003eUnit Cost Calculation\u003c\/h3\u003e\n\u003cp\u003eTo determine true Cost of Goods Sold (COGS), you must detail direct costs for every unit. This granular view separates profitable products from those that only look good on paper. Focus on minimizing variability in your material sourcing agreements now.\u003c\/p\u003e\n\u003cp\u003eFor each of the five products, your unit cost calculation must sum these core elements:\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eDirect Material Costs (Bill of Materials)\u003c\/li\u003e\n\u003cli\u003eDirect Assembly Labor Hours\u003c\/li\u003e\n\u003cli\u003eAllocated Cleanroom Overhead Rate\u003c\/li\u003e\n\u003cli\u003ePackaging and Inspection Costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"step-circle step3\"\u003e3\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003eStep 4\n: \u003cspan style=\"color: #126CFF;\"\u003eModel Capital Expenditures\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n\u003cdiv class=\"right-row4\"\u003e\n\u003ch3\u003eCapEx Foundation\u003c\/h3\u003e\n\u003cp\u003eModeling capital expenditures defines your operational ceiling before you sell a single device. This isn't just budgeting; it sets the physical limits for your Step 3 manufacturing plan. If the \u003cstrong\u003eAdvanced CNC Machining Center at $350,000\u003c\/strong\u003e is delayed, your ability to produce high-precision surgical tools stops dead. You must sequence these large purchases against your funding drawdown schedule.\u003c\/p\u003e\n\u003cp\u003eThe total \u003cstrong\u003e$1,115,000\u003c\/strong\u003e investment must be fully itemized across machinery, tooling, and cleanroom buildout, including the \u003cstrong\u003e$200,000 Cleanroom Setup\u003c\/strong\u003e. Failure to account for these upfront costs means you will run out of cash before achieving scale. Honestly, this is where most hardware startups fail to plan properly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"left-row4\"\u003e\n\u003cdiv class=\"tips-box\"\u003e\n\u003ch3\u003eOpEx Linkage\u003c\/h3\u003e\n\u003cp\u003eYou must lock down the \u003cstrong\u003e$43,800 monthly fixed operating expenses (OpEx)\u003c\/strong\u003e figure now. This number is your minimum monthly burn rate covering salaries, rent, and utilities before any revenue comes in. Crucially, check if this OpEx already includes the depreciation expense tied to the new \u003cstrong\u003e$1,115,000\u003c\/strong\u003e in assets you just modeled. If it doesn't, your break-even point calculation in Step 6 will be wrong.\u003c\/p\u003e\n\u003cp\u003eDefintely map every major purchase to a specific production milestone. This spending dictates your timeline for hitting the 2026 sales target of 100 Portable Ultrasounds. Here’s the quick math: if depreciation is excluded from the $43.8k, you need to add it back to find the true cash burn. This requires careful coordination with your accounting team.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eVerify asset useful lives for depreciation schedules.\u003c\/li\u003e\n\u003cli\u003eConfirm $43.8k covers all non-production overhead.\u003c\/li\u003e\n\u003cli\u003eTie large CapEx payments to specific funding tranches.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"step-circle step4\"\u003e4\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003eStep 5\n: \u003cspan style=\"color: #126CFF;\"\u003eBuild the Organizational Chart\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n\u003cdiv class=\"left-row5\"\u003e\n\u003ch3\u003eHeadcount Justification\u003c\/h3\u003e\n\u003cp\u003eBuilding the team of \u003cstrong\u003e65 Full-Time Equivalents (FTEs)\u003c\/strong\u003e defines your initial operational capacity. This structure must support the five planned devices and the necessary Quality Management System (QMS) requirements. The \u003cstrong\u003e$180,000 salary\u003c\/strong\u003e for the Head of R\u0026amp;D anchors your innovation pipeline, which is key to meeting the multi-year product launch schedule. Getting this initial mix right prevents immediate operational bottlenecks in design and compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"right-row5\"\u003e\n\u003cdiv class=\"tips-box\"\u003e\n\u003ch3\u003eScaling Headcount\u003c\/h3\u003e\n\u003cp\u003eTie future hiring directly to production volume milestones. For instance, scaling from \u003cstrong\u003e100 Portable Ultrasounds\u003c\/strong\u003e shipped in 2026 to \u003cstrong\u003e550 by 2030\u003c\/strong\u003e requires proportional scaling in manufacturing labor and quality assurance staff. Ensure the current \u003cstrong\u003e$43,800 monthly fixed operating expenses (OpEx)\u003c\/strong\u003e can absorb the initial 65 salaries before triggering significant revenue. This headcount plan needs constant review against unit cost targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"step-circle step5\"\u003e5\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003eStep 6\n: \u003cspan style=\"color: #126CFF;\"\u003eCreate 5-Year Financial Projections\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n\u003cdiv class=\"right-row6\"\u003e\n\u003ch3\u003eConfirming Breakeven Velocity\u003c\/h3\u003e\n\u003cp\u003eBuilding the 5-year projection hinges on validating that aggressive \u003cstrong\u003eMonth 1 breakeven\u003c\/strong\u003e goal. You must tie projected unit volume growth directly to pricing assumptions. For instance, if the Surgical Stapler starts at \u003cstrong\u003e$500\u003c\/strong\u003e and hits \u003cstrong\u003e$520\u003c\/strong\u003e by 2030, that price escalator must cover rising COGS and fixed overhead. If unit sales lag early on, that Month 1 target collapses fast. This model tests if your sales velocity assumptions are realistic enough to support your burn rate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"left-row6\"\u003e\n\u003cdiv class=\"tips-box\"\u003e\n\u003ch3\u003eValidate Month 1 Burn\u003c\/h3\u003e\n\u003cp\u003eTo confirm that aggressive Month 1 breakeven, calculate required gross profit against the \u003cstrong\u003e$43,800 monthly fixed operating expenses\u003c\/strong\u003e (OpEx). If 2026 sales carry a \u003cstrong\u003e50% commission\u003c\/strong\u003e structure, your net margin on sales is immediately tight. You need enough volume to cover that $43.8k OpEx plus the variable costs. If sales start slow, say only \u003cstrong\u003e100 Portable Ultrasounds\u003c\/strong\u003e shipped that first month, the revenue won't cover the burn, defintely pushing breakeven past Month 1.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"step-circle step6\"\u003e6\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003eStep 7\n: \u003cspan style=\"color: #126CFF;\"\u003eDetermine Funding Needs \u0026amp; Risks\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n\u003cdiv class=\"left-row7\"\u003e\n\u003ch3\u003eCash Threshold\u003c\/h3\u003e\n\u003cp\u003eYou need capital to bridge the gap until sales cover fixed costs. The absolute minimum cash requirement identified is \u003cstrong\u003e$1,097,000\u003c\/strong\u003e. This number covers initial operating expenses, like the \u003cstrong\u003e$43,800\u003c\/strong\u003e monthly overhead, plus initial inventory and regulatory hurdles. If you raise less, you risk running out of runway before hitting critical milestones. Securing this floor amount is non-negotiable for operational continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"right-row7\"\u003e\n\u003cdiv class=\"tips-box\"\u003e\n\u003ch3\u003eUpside Justification\u003c\/h3\u003e\n\u003cp\u003eInvestors look past the burn rate to the potential payoff. This model projects an aggressive \u003cstrong\u003e7116% Return on Equity (ROE)\u003c\/strong\u003e, signaling massive shareholder value creation if execution holds. Furthermore, Year 5 EBITDA hits an eye-watering \u003cstrong\u003e$2,537 million\u003c\/strong\u003e. What this estimate hides is the dependency on hitting the aggressive sales targets outlined in Step 6. We must defintely model sensitivities around these projections.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"step-circle step7\"\u003e7\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e","brand":"FinancialModelsLab","offers":[{"title":"Default Title","offer_id":49303860609267,"sku":"medical-device-manufacturing-business-planning","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0522\/6191\/2762\/files\/medical-device-manufacturing-business-planning.webp?v=1782686685","url":"https:\/\/financialmodelslab.com\/products\/medical-device-manufacturing-business-planning","provider":"Financial Models Lab","version":"1.0","type":"link"}